Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of BioCentury, Week in Review: Sales and Marketing

BioCentury, Week in Review Current Issue
  • Qiagen, General Electric sales and marketing update

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands General Electric Co. (NYSE:GE), Fairfield, Conn. Business: Pharmacogenetics Qiagen said General Electric's Clarient Diagnostic Services Inc. company will now …

    Published on 2/4/2013
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cardiovascular, Inflammation Sanofi launched LeGoo gel in the U.S. for temporary endovascular occlusion of blood vessels during surgical procedures. The pharma …

    Published on 2/4/2013
  • SciClone, Sanofi sales and marketing update

    SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Neurology, Cardiovascular, Genitourinary SciClone announced that it and Sanofi agreed to group …

    Published on 2/4/2013
  • BioPorto Diagnostics, Siemens sales and marketing update

    BioPorto Diagnostics A/S (CSE:BIOPOR), Gentofte, Denmark Siemens AG (Euronext:SIE; NYSE:SI), Munich, Germany Business: Diagnostic BioPorto received notification from Siemens that it halted sale activities concerning …

    Published on 1/28/2013
  • Hybrigenics sales and marketing update

    Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Proteomics, Supply/Service Hybrigenics' Hybrigenics Services subsidiary launched a worldwide service to identify interactions between small molecules and …

    Published on 1/28/2013
  • KV Pharmaceutical, Perrigo sales and marketing update

    KV Pharmaceutical Co. (OTCQB:KVPHQ), St. Louis, Mo. Perrigo Co. (NASDAQ:PRGO; Tel Aviv:PRGO), Allegan, Mich. Business: Infectious KV's Ther-Rx Corp. subsidiary and Perrigo relaunched Gynazole-1 butoconazole nitrate …

    Published on 1/28/2013
  • Merck KGaA, Pfizer sales and marketing update

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Autoimmune Merck's Merck Serono S.A. division and Pfizer launched a $0 co-pay program for Rebif interferon beta-1a to treat …

    Published on 1/28/2013
  • Merus Labs International, POA Pharma Scandinavia AB, Proximum d.o.o., SPCare Lda sales and marketing update

    Merus Labs International Inc. (TSX:MSL; NASDAQ:MSLI), Toronto, Ontario POA Pharma Scandinavia AB, Gothenburg, Sweden Proximum d.o.o., Zagreb, Croatia SPCare Lda, Lisbon, Portugal Business: Genitourinary Merus granted …

    Published on 1/28/2013
  • Recordati, Lundbeck sales and marketing update

    Recordati S.p.A. (Milan:REC), Milan, Italy H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology, Cardiovascular Recordati completed its acquisition of a portfolio of H. Lundbeck's non-core products. …

    Published on 1/28/2013
  • Vitro Diagnostics sales and marketing update

    Vitro Diagnostics Inc. (OTCBB:VODG), Golden, Colo. Business: Gene/Cell therapy, Supply/Service Vitro launched native and labeled osteoblasts derived from human mesenchymal stem cells (MSCs) worldwide for use in …

    Published on 1/28/2013
  • Werfen sales and marketing update

    Werfen Group S.A., Barcelona, Spain Business: Diagnostic Werfen's Inova Diagnostics Inc. subsidiary launched its Bio-Flash chemiluminescent analyzer worldwide to aid in diagnosing autoimmune disease. The product uses …

    Published on 1/28/2013
  • AbbVie sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Autoimmune AbbVie launched Humira adalimumab in the U.K. to treat patients aged 6-17 years with severely active Crohn's disease who failed, are intolerant to or have …

    Published on 1/21/2013
  • Apeiron Biologics, Paladin sales and marketing update

    Apeiron Biologics AG, Vienna, Austria Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Business: Cancer Apeiron granted Paladin exclusive rights to commercialize APN311, a chimeric mAb against GD2, in Canada and sub-…

    Published on 1/21/2013
  • Atossa Genetics sales and marketing update

    Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Diagnostic Atossa launched its ForeCYTE Breast Health Test in the U.S. to differentiate between normal, premalignant and malignant tumor cells as an adjunct …

    Published on 1/21/2013
  • Duchesnay, Tzamal sales and marketing update

    Duchesnay Inc., Blainville, Quebec Tzamal Medical Group Ltd., Petah Tikva, Israel Business: Gastrointestinal Duchesnay granted Tzamal exclusive rights to commercialize Diclectin doxylamine/pyridoxine in Israel to manage…

    Published on 1/21/2013
  • Ipsen, Teijin sales and marketing update

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Teijin Pharma Ltd., Tokyo, Japan Business: Endocrine/Metabolic Teijin launched Somatuline lanreotide acetate in Japan to treat acromegaly and …

    Published on 1/21/2013
  • Ironwood, AstraZeneca sales and marketing update

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Gastrointestinal Ironwood said in its 4Q12 earnings that it received rights from AstraZeneca to …

    Published on 1/21/2013
  • J&J, LabCorp sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostic Johnson & Johnson's Veridex LLC unit granted LabCorp rights to use CellSearch …

    Published on 1/21/2013
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology Pfizer launched Quillivant XR in the U.S. to treat ADHD. FDA approved the once-daily, extended-release liquid methylphenidate last September. Quillivant XR was …

    Published on 1/21/2013
  • Pronova, Takeda sales and marketing update

    Pronova Biopharma ASA (OSE:PRON), Lysaker, Norway Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic Takeda launched Lotriga in Japan to treat hyperlipidemia. Takeda has exclusive, …

    Published on 1/21/2013
  • Academy Medical LLC, Cardium sales and marketing update

    Academy Medical LLC, West Palm Beach, Fla. Cardium Therapeutics Inc. (NYSE-M:CXM), San Diego, Calif. Business: Dermatology Cardium granted Academy Medical rights to commercialize wound care product Excellagen to U.S. …

    Published on 1/14/2013
  • Aegerion sales and marketing update

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Business: Endocrine/Metabolic Aegerion provided pricing for its homozygous familial hypercholesterolemia (hoFH) drug Juxtapid lomitapide in a presentation at…

    Published on 1/14/2013
  • Affymax, Takeda, DSI Renal sales and marketing update

    Affymax Inc. (NASDAQ:AFFY), Palo Alto, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan DSI Renal, Nashville, Tenn. Business: Hematology Affymax and partner Takeda entered into a supply agreement for …

    Published on 1/14/2013
  • Allergy Therapeutics, Paladin sales and marketing update

    Allergy Therapeutics plc (LSE:AGY), London, U.K. Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Business: Inflammation Paladin acquired exclusive Canadian distribution and commercialization rights for Pollinex-R ragweed …

    Published on 1/14/2013
  • Ariosa Diagnostics, The Doctors Laboratory Ltd. (TDL) sales and marketing update

    Ariosa Diagnostics Inc., San Jose, Calif. The Doctors Laboratory Ltd. (TDL), London, U.K. Business: Diagnostic. TDL will promote and distribute Ariosa's Harmony Prenatal Test in the U.K. through TDL's reference …

    Published on 1/14/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?